Drug Profile
AZD 8108
Alternative Names: AZD8108Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Suicidal ideation
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Suicidal-ideation(In volunteers) in USA (PO, Liquid)
- 06 Feb 2017 AstraZeneca divests the development of AZD 8108 to an unknown company (AstraZeneca pipeline, February 2017)
- 01 Nov 2014 Phase-I clinical trials in Suicidal ideation (In volunteers) in USA (PO)